Sandwich ELISA, Biotin-labelled antibody
Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Limit of Detection
- European Union: for in vitro diagnostic use
- Rest of the world: for research use only!
- Measurement of IGF-II in non-extracted serum and plasma samples
- Calibrated against the International Standard: WHO NIBSC 96/538
- No interference by IGF-binding proteins through excess IGF-I
- Precise measurement of very low IGF-II levels: high sensitivity of 0.02 ng/ml
- Inter- and Intra-Assay variance: maximal 7.2 and 6.6%
Growth hormone and factor-related products
The insulin-like growth factors (IGF)-1 and –2 play a pivotal role in the regulation of proliferation and differentiation
of several tissue types. IGF-1 also called Somatomedin C has a molecular weight of 7.469 kDa.
Its expression is mainly regulated by Growth Hormone and nutrition. But several hormones and peptide factors
are known to influence IGF-2 synthesis in different tissues. Bioavailability of the IGFs is regulated by specific
binding proteins (IGFBP). Beside the high affinity Insulin-like Growth Factor Binding Proteins 1-6, IGFs are also
bound be IGFBP-related Proteins. These binding proteins bind IGF-1 and IGF-2 with the same affinity or prefer IGF-2. Direct measurement of IGFs in serum samples without pretreatment results in false values because of the extremely slow dissociation of the IGF/IGFBP complexes during the assay incubation only a part of the IGF-2 in the specimen can bind to the antibodies and be detected.
Therefore, various techniques were applied to physically separate IGF-2 from its binding proteins before measurement, including (a) size exclusion chromatography under acidic conditions, (b) solid-phase extraction and (c) acid-ethanol extraction. These techniques, however, are either inconvenient or time-consuming or give incomplete and not-reproducible recoveries.
This assay is easy, fast and results do not depend on the binding protein concentration of the sample. Its based on the high specificity of the employed antibodies for IGF-2. There is virtually no cross-reactivity with IGF-1. This allows the separation of IGF-2 from the binding proteins by acidification and blocking of the free binding proteins with IGF-1. Thus, the endogenous IGF-2 is free in solution.